Therapeutic Response Statement (Sensitivity)
This therapeutic response statement supports the relationship that 17p deletion status confers therapeutic sensitivity to Zanubrutinib in patients with Chronic Lymphocytic Leukemia.
This statement is based on a regulatory approval from the Health Service Executive:
As monotherapy for the treatment of adult patients with chronic lymphocytic leukaemia (CLL), who are treatment naive and have del(17p) and/or TP53-mutated disease.